CSL:NYSECarlisle Companies Incorporated Analysis
Data as of 2026-06-25 - not real-time
$389.56
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Technical outlook: Carlisle (CSL) is trading at $389.56, comfortably above its 20‑day ($349.78), 50‑day ($350.01) and 200‑day ($345.36) moving averages, while the MACD remains bullish and the RSI sits at 66, indicating momentum but approaching overbought levels. The stock is near its short‑term resistance of $397.16 with only a modest 5.3% upside potential per the model, and the market sentiment is in the "Extreme Greed" zone (Fear & Greed Index 87).
Fundamental outlook: The company posts a solid ROE of 38% and generates strong cash flow, supporting a sustainable dividend (25% payout, 1.16% yield). However, leverage is high (debt‑to‑equity ~175%) and the DCF‑derived fair value of $182 is far below the current price, suggesting limited upside. PE (22.7x) is below the industry average (31.9x) and forward PE (16.6x) points to earnings growth, but volatility is elevated (44% 30‑day) and beta exceeds 1, flagging heightened market risk.
Fundamental outlook: The company posts a solid ROE of 38% and generates strong cash flow, supporting a sustainable dividend (25% payout, 1.16% yield). However, leverage is high (debt‑to‑equity ~175%) and the DCF‑derived fair value of $182 is far below the current price, suggesting limited upside. PE (22.7x) is below the industry average (31.9x) and forward PE (16.6x) points to earnings growth, but volatility is elevated (44% 30‑day) and beta exceeds 1, flagging heightened market risk.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near resistance with limited upside
- RSI approaching overbought territory
- Strong cash flow but high leverage
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Forward earnings growth (forward PE 16.6x)
- Sustainable dividend payout
- Debt level requiring monitoring
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- High ROE and consistent free cash flow
- Valuation gap versus DCF fair value
- Potential for debt reduction and margin expansion
Key Metrics & Analysis
Financial Health
Revenue Growth-4.00%
Profit Margin14.57%
P/E Ratio22.7
ROE38.23%
ROA10.88%
Debt/Equity174.73
P/B Ratio9.5
Op. Cash Flow$1.1B
Free Cash Flow$722.2M
Industry P/E32.0
Technical Analysis
TrendNeutral
RSI66.2
Support$327.75
Resistance$397.16
MA 20$349.78
MA 50$350.01
MA 200$345.36
MACDBullish
VolumeIncreasing
Fear & Greed Index87.16
Valuation
Fair Value$182.23
Target Price$410.14
Upside/Downside5.28%
GradeOvervalued
TypeBlend
Dividend Yield1.16%
Risk Assessment
Beta1.21
Volatility44.54%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.